Researcher Profile

Researcher Profile

David Waning, PhD

David Waning, PhD

Associate Professor, Department of Cellular and Molecular Physiology
Scientific Program:Experimental Therapeutics
dlw83@psu.edu
View Website

Research Interests

Dr. David Waning's research focuses on the emerging importance of bone-muscle crosstalk in aging and disease.

The overarching goal of his research program is to discover and characterize molecular mechanisms that impair musculoskeletal health in disease and aging. Bone and muscle are tightly coupled during growth and development, and also during aging and disease yet the cellular and molecular mechanisms linking these two tissues are not well understood. The Waning lab is developing novel therapeutic approaches that improve musculoskeletal health in pre-clinical models of cancer and chemotherapy-induced sequelae, osteoporosis and aging.

The major aims of Dr. Waning's research are to identify and characterize signal mediators of bone-muscle crosstalk that affect musculoskeletal health. He is especially interested in identifying targets of oxidative stress that affect bone and muscle function; understanding muscle weakness in cachexia; cachexia and the relative contribution of muscle wasting and contractile dysfunction; and bone-muscle crosstalk in rare bone diseases.

  • Bone and Bones
  • Neoplasms
  • Muscles
  • Neoplasm Metastasis
  • Muscle Weakness
  • Proteins
  • Therapeutics
  • Bone Neoplasms
  • Skeletal Muscle
  • Breast Neoplasms
  • DNA Damage
  • Osteoblasts

Recent Publications

2019

Waning, D, Guise, TA & Mohammad, KS 2019, 'A “Connexin” Responsible for the Fatal Attraction of Cancer to Bone' Cell Metabolism, vol. 29, no. 1, pp. 6-8. https://doi.org/10.1016/j.cmet.2018.12.014
Huot, JR, Essex, AL, Gutierrez, M, Barreto, R, Wang, M, Waning, D, Plotkin, LI & Bonetto, A 2019, 'Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles', Cancers, vol. 11, no. 4, 571. https://doi.org/10.3390/cancers11040571

2017

Wright, LE, Harhash, AA, Kozlow, WM, Waning, D, Regan, JN, She, Y, John, SK, Murthy, S, Niewolna, M, Marks, AR, Mohammad, KS & Guise, TA 2017, 'Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo', Oncotarget, vol. 8, no. 5, pp. 8406-8419. https://doi.org/10.18632/oncotarget.14139
Ross, MH, Esser, AK, Fox, GC, Schmieder, AH, Yang, X, Hu, G, Pan, D, Su, X, Xu, Y, Novack, DV, Walsh, T, Colditz, GA, Lukaszewicz, GH, Cordell, E, Novack, J, Fitzpatrick, JAJ, Waning, D, Mohammad, KS, Guise, TA, Lanza, GM & Weilbaecher, KN 2017, 'Bone-induced expression of integrin b3 enables targeted nanotherapy of breast cancer metastases', Cancer Research, vol. 77, no. 22, pp. 6299-6312. https://doi.org/10.1158/0008-5472.CAN-17-1225
Wang, H, Cai, S, Bailey, BJ, Saadatzadeh, MR, Ding, J, Tonsing-Carter, E, Georgiadis, TM, Gunter, TZ, Long, EC, Minto, RE, Gordon, KR, Sen, SE, Cai, W, Eitel, JA, Waning, D, Bringman, LR, Wells, CD, Murray, ME, Sarkaria, JN, Gelbert, LM, Jones, DR, Cohen-Gadol, AA, Mayo, LD, Shannon, HE & Pollok, KE 2017, 'Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist', Journal of neurosurgery, vol. 126, no. 2, pp. 446-459. https://doi.org/10.3171/2016.1.JNS152513
Regan, JN, Mikesell, C, Reiken, S, Xu, H, Marks, AR, Mohammad, KS, Guise, TA & Waning, D 2017, 'Osteolytic breast cancer causes skeletal muscle weakness in an immunocompetent syngeneic mouse model', Frontiers in Endocrinology, vol. 8, no. DEC, 358. https://doi.org/10.3389/fendo.2017.00358
Regan, JN, Trivedi, T, Guise, TA & Waning, D 2017, 'The Role of TGFβ in Bone-Muscle Crosstalk', Current Osteoporosis Reports, vol. 15, no. 1, pp. 18-23. https://doi.org/10.1007/s11914-017-0344-5

2016

Barreto, R, Waning, D, Gao, H, Liu, Y, Zimmers, TA & Bonetto, A 2016, 'Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs', Oncotarget, vol. 7, no. 28, pp. 43442-43460. https://doi.org/10.18632/oncotarget.9779
Regan, JN, Waning, D & Guise, TA 2016, 'Skeletal muscle Ca2+ mishandling: Another effect of bone-to-muscle signaling', Seminars in Cell and Developmental Biology, vol. 49, pp. 24-29. https://doi.org/10.1016/j.semcdb.2015.11.007

2015

Waning, D, Mohammad, KS, Reiken, S, Xie, W, Andersson, DC, John, S, Chiechi, A, Wright, LE, Umanskaya, A, Niewolna, M, Trivedi, T, Charkhzarrin, S, Khatiwada, P, Wronska, A, Haynes, A, Benassi, MS, Witzmann, FA, Zhen, G, Wang, X, Cao, X, Roodman, GD, Marks, AR & Guise, TA 2015, 'Excess TGF-β mediates muscle weakness associated with bone metastases in mice', Nature Medicine, vol. 21, no. 11, pp. 1262-1271. https://doi.org/10.1038/nm.3961
Cheng, YH, Streicher, DA, Waning, D, Chitteti, BR, Gerard-O'Riley, R, Horowitz, MC, Bidwell, JP, Pavalko, FM, Srour, EF, Mayo, LD & Kacena, MA 2015, 'Signaling pathways involved in megakaryocyte-mediated proliferation of osteoblast lineage cells', Journal of Cellular Physiology, vol. 230, no. 3, pp. 578-586. https://doi.org/10.1002/jcp.24774

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)